1. Kay BA, Bopp CA, Wells JG. Isolation and identiAEcation of Vibrio chol- patients with Laennec's cirrhosis. Ann NY Acad Sci 1975; 252: erae O1 from fecal specimens. In: Wachsmuth K, Blake PA, Olsvik 348 0 52. O, eds. Vibrio cholerae and cholera: molecular to global perspectives. 22. Sciortino CV, Johnson JA, Hamad A. Vitek system antimicrobial suscepti-Washington, DC: American Society for Microbiology, 1994:3 0 25. bility testing of O1, O139, and non-O1 Vibrio cholerae. J Clin Microbiol
2. Morris JG Jr. Non 0 O group 1 Vibrio cholerae strains not associated with 1996; 34:897 0 900. epidemic disease. In: Wachsmuth K, Blake PA, Olsvik O, eds. Vibrio 23. Chuang YC, Liu JW, Ko WC, Lin KY, Wu JJ, Huang KY. In vitro cholerae and cholera: molecular to global perspectives. Washington, synergism between cefotaxime and minocycline against Vibrio vulniAE- DC: American Society for Microbiology, 1994:103 0 15. cus. Antimicrob Agents Chemother 1997; 41:2214 0 7.
3. Safrin S, Morris JG Jr, Adams M, Pons V, Jacobs R, Conte JE Jr. Non 0 24. Chuang YC, Ko WC, Wang ST, et al. Minocycline and cefotaxime in the O:1 Vibrio cholerae bacteremia: case report and review. Rev Infect Dis treatment of experimental murine Vibrio vulniAEcus infection. Antimi-1988; 10:1012 0 7. crob Agents Chemother 1998; 42:1319 0 22.